REKAMBYS

This brand name is authorized in Austria, Estonia, Finland, France, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Poland, United Kingdom

Active ingredients

The drug REKAMBYS contains one active pharmaceutical ingredient (API):

1 Rilpivirine UNII FI96A8X663 - RILPIVIRINE

Rilpivirine is a diarylpyrimidine NNRTI of HIV-1. Rilpivirine activity is mediated by non-competitive inhibition of HIV-1 reverse transcriptase (RT). Rilpivirine does not inhibit the human cellular DNA polymerases α, β and γ. Read about Rilpivirine

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
REKAMBYS Prolonged-release suspension for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J05AG05	Rilpivirine	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AG Non-nucleoside reverse transcriptase inhibitors
Discover more medicines within J05AG05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1835535, 1835546
Country: FI	Lääkealan turvallisuus- ja kehittämiskeskus	Identifier(s): 093653
Country: FR	Base de données publique des médicaments	Identifier(s): 60150638
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9040
Country: IT	Agenzia del Farmaco	Identifier(s): 049280011, 049280023
Country: JP	医薬品医療機器総合機構	Identifier(s): 6250409A1022, 6250409A2029
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1091686, 1091687
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100445800, 100445816